Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Enzymatically triggered glucose-releasing scaffolds as nutritional supports for millimeter-scale tissue engineering.

Laowpanitchakorn P., Piantino M., Matsuo T., Matsusaki M.

Laboratory Study on Hip, published in Mater Today Bio (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Mater Today Bio (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42540439
DOI
10.1016/j.mtbio.2026.103474

Abstract (original English)

Construction of millimeter-sized tissues to mimic real human tissue or organ is still challenging, as oxygen and nutrients have a diffusion limit of only 100-200 μm from blood vessels. Almost all mammalian cells except red blood cells and platelets need a glucose supply to support their metabolic activities and functions. Inspired by the properties of blood vessels, we developed an alginate scaffold that is capable to release glucose by hydrolysis of glycogen via enzymes such as amyloglucosidase in this study. The scaffold can be flexibly shaped into glucose-releasing capsules (Glc-RCs) and glucose-releasing fibers (Glc-RFs). It was demonstrated that Glc-RCs can provide sustained release of glucose for up to 4 days and have no negative effect on C2C12 mouse myoblast cell and human adipose-derived mesenchymal stem cell proliferation. Glc-RCs could also support differentiation of C2C12 into myotubes after 7 days of application without the need for media replenishment. Glc-RFs were incorporated into millimeter-scale 3D tissue-engineered constructs, where they reduced the apoptotic activity of normal human dermal fibroblasts (NHDFs) located within approximately 1000 μm from the fibers. In particular, the relationship between glucose diffusion distance and resulting cellular responses like apoptosis has not previously been documented in other glucose-releasing material studies. Thus

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research